Radionuklidbehandling af neuroendokrine tumorer
Research output: Contribution to journal › Journal article › Research › peer-review
Peptide receptor radionuclide therapy using somatostatin analogues labelled with beta-emitting isotopes can be given to patients with metastasized or inoperable neuroendocrine tumours provided these have increased uptake on octreotide scintigraphy. This is a brief review of the treatment principle, indications and contraindications and practices with (177)Lu-DOTATATE treatment used at Rigshospitalet. Side effects are generally mild and reversible. Severe long-term side effects are rare. The majority of patients will experience increased quality of life and partial tumour reduction or stabilization for a period of time. However, up to 20% will experience no treatment effect.
|Journal||Ugeskrift for Laeger|
|Number of pages||4|
|Publication status||Published - 25 Oct 2010|